• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, Feb. 3

Ranbaxy Laboratories Ltd has received the US Food and Drug Administration approval to sell amoxicillin and clavulanate potassium for oral suspension in three strengths. In an official statement, the company said that the Ranbaxy formulation had been judged as bio-equivalent of GlaxoSmithKline's registered anti-infection drug Augmentin, which has a total sales of $216 million. Augmentin's sales for 600 mg, 42.9 mg (base) and 5 ml, the three versions that Ranbaxy now has marketing approval for, are believed to account for $136.9 million in sales. The oral suspension of the drugs will be available in April 2007, said Mr Jim Meehan, Vice-President, Sales and Marketing, Ranbaxy Pharmaceuticals Inc, the Florida-based subsidiary of Ranbaxy Laboratories Ltd.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
`Promoters have no plan to sell stake in Polaris'

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line